Maravai LifeSciences Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Trey Martin

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage	32.6%
CEO tenure	less than a year
CEO ownership	0.2%
Management average tenure	2.1yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Trey Martin's remuneration changed compared to Maravai LifeSciences Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$131m
Dec 31 2023	US$2m	US$750k	-US$119m
Sep 30 2023	n/a	n/a	US$25m
Jun 30 2023	n/a	n/a	US$75m
Mar 31 2023	n/a	n/a	US$153m
Dec 31 2022	US$15m	US$660k	US$220m

Compensation vs Market: Trey's total compensation ($USD2.30M) is above average for companies of similar size in the German market ($USD1.49M).

Compensation vs Earnings: Trey's compensation has been consistent with company performance over the past year.

CEO

Trey Martin (49 yo)

less than a year

Tenure

US$2,301,864

Compensation

Mr. William E. Martin, III, also known as Trey, was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. since December 5, 2022 until July 27, 2023 and is its Chief Executive Office...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Carl Hull	Co-Founder & Executive Chairman	3.7yrs	US$5.22m	0.22% $ 3.6m
William Martin	Chief Executive Officer	less than a year	US$2.30m	0.16% $ 2.6m
Kevin Herde	Executive VP & CFO	7.2yrs	US$2.79m	0.022% $ 362.3k
Peter Leddy	Executive VP & Chief Administrative Officer	2.1yrs	US$2.83m	0.030% $ 489.7k
Christine Dolan	Executive VP & GM of Cygnus Technologies	6.8yrs	US$2.26m	0.020% $ 318.9k
Andrew Burch	President of Nucleic Acid Production	1.3yrs	US$2.99m	0.024% $ 391.5k
Debra Hart	Senior Director of Investor Relations	no data	no data	no data
Kurt Oreshack	Executive VP	3.7yrs	US$701.40k	0.019% $ 313.4k
Rebecca Buzzeo	Executive VP & Chief Commercial Officer	1.4yrs	no data	0.015% $ 241.1k
Kate Broderick	Chief Innovation Officer	1.4yrs	no data	no data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: MAR's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Carl Hull	Co-Founder & Executive Chairman	3.7yrs	US$5.22m	0.22% $ 3.6m
John DeFord	Independent Director	less than a year	US$435.03k	no data
Constantine Mihas	Non-Independent Director	3.7yrs	US$370.48k	0.0032% $ 52.4k
Sean Cunningham	Non-Independent Director	3.7yrs	US$367.98k	0.0032% $ 52.4k
Gregory Lucier	Independent Director	3.7yrs	US$360.48k	0.023% $ 381.2k
Susannah Gray	Independent Director	3.7yrs	US$395.48k	0.027% $ 442.4k
Benjamin Daverman	Non-Independent Director	3.7yrs	US$360.48k	0.0032% $ 52.4k
Luke Marker	Non-Independent Director	3.7yrs	US$360.48k	0.0032% $ 52.4k
Murali Prahalad	Independent Director	3.7yrs	US$367.98k	0.016% $ 255.1k
Jessica Hopfield	Independent Director	3.7yrs	US$387.98k	0.050% $ 809.9k
Anat Ashkenazi	Independent Director	3.7yrs	US$392.98k	0.012% $ 197.5k

3.7yrs

Average Tenure

59yo

Average Age

Experienced Board: MAR's board of directors are considered experienced (3.7 years average tenure).

Maravai LifeSciences Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. Announces Board Changes

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.091 loss per share (vs US$0.001 loss in 1Q 2023)

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai LifeSciences Holdings, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$0.90 loss per share (vs US$1.67 profit in FY 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Investor sentiment deteriorates as stock falls 16%

Maravai LifeSciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.34 profit in 3Q 2022)

Now 27% undervalued after recent price drop

Maravai LifeSciences Holdings, Inc. Provides Updated Earnings Guidance for the Full Year 2023

Maravai LifeSciences Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 15%

Maravai Lifesciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: US$0.05 loss per share (vs US$0.54 profit in 2Q 2022)

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Maravai LifeSciences Holdings, Inc. Announces Board Changes

New major risk - Share price stability

Investor sentiment improves as stock rises 25%

First quarter 2023 earnings released: US$0.001 loss per share (vs US$0.51 profit in 1Q 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.67 (vs US$1.59 in FY 2021)

Maravai LifeSciences Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.46 in 3Q 2021)

Investor sentiment deteriorated over the past week

Maravai Lifesciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

Maravai LifeSciences Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Investor sentiment deteriorated over the past week

Maravai LifeSciences Announces CEO Leadership Transition

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.44 in 2Q 2021)

Maravai LifeSciences Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Maravai LifeSciences, Inc. Appoints Peter Leddy as Executive Vice President and Chief Administrative Officer

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: US$0.51 (vs US$0.24 in 1Q 2021)

Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Maravai LifeSciences Holdings, Inc. to Report Q1, 2022 Results on May 05, 2022

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 12, 2022

Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Revised Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.47 (vs US$0.62 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $1 billion.

Maravai LifeSciences Holdings, Inc. Provides Financial Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$0.44 (vs US$0.021 loss in 2Q 2020)

Investor sentiment improved over the past week

Co-Founder, President & Executive VP of Corporate Development Eric Tardif has left the company

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.24 (vs US$0.021 loss in 1Q 2020)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team